AZIYO BIOLOGICS(US:AZYO)2025-11-12 22:01Financial Performance - Net sales for the three months ended September 30, 2025, were $3,323,000, down 9.2% from $3,662,000 in the same period of 2024[29]. - Gross profit for the three months ended September 30, 2025, was $1,853,000, compared to $1,791,000 for the same period in 2024, reflecting a slight increase of 3.5%[29]. - The net loss attributable to common stockholders for the three months ended September 30, 2025, was $3,868,000, compared to a net income of $1,067,000 in the same period of 2024[29]. - For the nine months ended September 30, 2025, the net loss was $17.4 million, compared to a net loss of $44.9 million for the same period in 2024, indicating a significant improvement[34]. - For the nine months ended September 30, 2025, the net loss was $8,050,000 compared to a net loss of $6,878,000 for the same period in 2024[93]. - The company reported a loss from operations of $5,208,000 for the three months ended September 30, 2025, compared to a loss of $9,175,000 in the same period of 2024[29]. - Loss from operations improved by 43.2% to $(5.2) million in Q3 2025 compared to $(9.2) million in Q3 2024[197]. Assets and Liabilities - Total current assets decreased from $26,172,000 as of December 31, 2024, to $18,378,000 as of September 30, 2025, a decline of approximately 29.7%[27]. - Cash and cash equivalents decreased from $13,239,000 as of December 31, 2024, to $4,721,000 as of September 30, 2025, a decline of approximately 64.3%[27]. - The total liabilities increased from $82,387,000 as of December 31, 2024, to $73,325,000 as of September 30, 2025, a decrease of approximately 11%[27]. - The company’s total stockholders' equity (deficit) as of September 30, 2025, was $(43.9) million, compared to $(40.2) million as of September 30, 2024[34]. Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $7,061,000, a decrease of 35.5% from $10,966,000 in the prior year[29]. - Stock-based compensation for the nine months ended September 30, 2025, was $4.3 million, down from $6.7 million in the same period of 2024[34]. - General and administrative expenses decreased by 18.9% to $3.5 million in Q3 2025, primarily due to lower non-cash equity compensation[202]. - Total operating expenses decreased by $3.6 million, or 12.6%, to $25.0 million for the nine months ended September 30, 2025, compared to $28.6 million for the same period in 2024[208]. Research and Development - Research and development expenses increased to $1,088,000 for the three months ended September 30, 2025, from $702,000 in the same period of 2024, an increase of 55%[29]. - The company is aggressively pursuing the development of NXT-41 and NXT-41x, next-generation biologic scaffolds combined with local antibiotic delivery, reflecting heightened R&D activity[215]. - R&D expenses increased by $0.4 million, or 55.0%, to $1.1 million for the three months ended September 30, 2025, compared to $0.7 million for the same period in 2024[203]. Cash Flow and Financing - The company experienced a cash outflow of $20 million from operating activities for the nine months ended September 30, 2025, compared to $10.4 million in the prior year[34]. - The company anticipates using its new facility in Gaithersburg, Maryland for commercial production of new products, pending marketing authorization[68]. - The company may seek to raise additional capital through equity issuance or asset sales to finance operations[49]. - The company expects to incur operating losses and negative cash flows from operations for the foreseeable future as it advances the development and commercialization of NXT-41 and NXT-41x[224]. Discontinued Operations - The company completed the sale of its cardiac implantable electronic device (CIED) business for up to $88 million, with $80.3 million received at closing[42][44]. - The sale of the CIED business is classified as discontinued operations, significantly impacting the company's financial results[45]. - The divestiture of the CIED Business was completed on October 1, 2025, with related assets and liabilities classified as discontinued operations[95]. - The sale of the Orthobiologics Business generated $14.6 million, with potential additional earn-out payments of up to $20 million based on future sales[186]. Litigation and Legal Matters - As of September 30, 2025, there were 44 active lawsuits related to FiberCel, with 38 settlements reached but not yet paid[140]. - The company is involved in ongoing litigation against Medtronic regarding breach of the Tissue Product Supply Agreement, with discovery still ongoing[141]. - The total cash outlay for settled cases in the FiberCel Litigation amounted to $22.5 million, with $9.6 million covered by insurance proceeds[144]. - The Company recorded a total cash outlay of approximately $1.5 million for settled cases in the VBM Litigation, with an estimated liability of $3.7 million for the remaining cases as of September 30, 2025[148]. Market and Sales - The estimated U.S. market for biologic matrices is $1.5 billion, accounting for over 60% of reconstruction spending[172]. - The company continues to market SimpliDerm, a human-derived acellular dermal matrix, which is a key component of the Women's Health segment[168]. - The net sales for Women's Health for the nine months ended September 30, 2025, were $7.015 million, while Cardiovascular net sales were $2.007 million, totaling $9.022 million[162]. - The company has experienced seasonality in sales, with higher sales typically in the fourth quarter due to hospital purchasing patterns[223].